The Ultimate Guide to Bicalutamide: API Sourcing, Clinical Applications & Strategic Insights for Pharma Professionals
What is Bicalutamide?
Bicalutamide is a non-steroidal anti-androgen (NSAA) drug classified as a competitive inhibitor of the androgen receptor (AR).
Its chemical name is (RS)-N-[4-Cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide (CAS 90357-06-5).
As a first-generation AR antagonist, it binds to androgen receptors in target tissues, blocking testosterone and dihydrotestosterone (DHT) from stimulating prostate cancer growth.
Unlike chemotherapy, it specifically targets hormonal pathways without indiscriminate cell destruction
Is Bicalutamide Chemotherapy?
No, bicalutamide is not chemotherapy.
The key differentiators between Bicalutamide and Chemo:
Mechanism: Targets androgen receptors specifically (vs. chemotherapy’s non-selective cell destruction) 1
Side Effect Profile:
Lower hematologic toxicity (≤5% anemia vs. 80-90% with chemo)
No hair loss or severe nausea
Administration: Oral daily dosing (vs. IV infusion for most chemo)
Why This Matters for Manufacturers:
- No chemotherapy-related toxicity (e.g., hair loss, severe nausea).
- Lower risk of drug interactions compared to cytotoxic agents.
What Are the Brand Names of Bicalutamide?
Global Brands:
Casodex® (AstraZeneca) – Original patented brand
Cosudex® (Generic equivalents)
Regional Variations:
China: 朝晖先 (Zhāo huī xiān)
India: Bilutam, Bicaflo
Europe: Calutide, Kalumid
Formulation Types:
50mg film-coated tablets (standard)
Compounded topical gels (for gynecomastia prevention)
What Are the Brand Names of Darolutamide?
Global Primary Brand: Nubeqa® (marketed by Bayer/Orion Corporation)
Generic Names: Darolutamide (INN), darolutamidum (Latin)
Generic Availability: Limited; restricted to clinical trials and select markets.
Regional Variations:
China: 诺倍戈 (Nuò bèi gē)
Europe: Nubeqa (distributed by Orion Pharma)
Product Characteristics: White, oval, film-coated tablets engraved with “300” on one side and “BAYER” on the reverse
Market Insights:
- Pricing: ~$12,000/month in the U.S. (varies by region).
- Key Suppliers: Bayer HealthCare, Orion Pharma.
What is Bicalutamide Used For?
FDA/EMA-Approved Indications:
Advanced Prostate Cancer:
Combined with LHRH agonists (e.g., leuprolide) or post-orchiectomy for metastatic disease
RTOG 9601 trial showed 76.3% 12-year survival vs. 71.3% with placebo (P<0.001)
Early-Stage Prostate Cancer:
Adjuvant therapy post-radiation (150mg/day)
Off-Label Applications:
Gynecomastia Prevention: 0.5-1% topical gels
Androgenetic Alopecia: Nanoemulsion formulations (preclinical)
How Bicalutamide Works? (Mechanism of Action)
Bicalutamide executes its anti-cancer effects through a multi-step AR blockade:
Competitive Receptor Binding: High-affinity binding to AR ligand-binding domain (Kd=11nM)
Nuclear Translocation Inhibition: Prevents AR complex migration to the nucleus
DNA Binding Disruption: Blocks AR-DNA interaction at response elements
Co-activator Recruitment Prevention
Critical Note: At standard doses (50mg), it acts as an antagonist, but may exhibit partial agonist activity in high concentrations (>150mg) or resistant tumors.
Why It Stands Out:
- Minimal CNS penetration → fewer neurological side effects.
- Stable pharmacokinetics (almost no food interactions).
Bicalutamide Dosage and Administration
Standard Protocols:
Prostate Cancer Monotherapy: 150mg once daily
Combination with LHRH: 50mg once daily
Renal Impairment: No adjustment needed (hepatic clearance)
Administration: Morning dose with food (high-fat meal ↑ bioavailability 25%)
- Combination Therapy: With docetaxel: 60 mg/m² IV every 3 weeks for 6 cycles
Special Populations:
| Condition | Dose Adjustment | Rationale |
|---|---|---|
| Severe Hepatic Impairment | Avoid or take 25mg daily | ↓ Clearance → ↑ AUC |
| Concurrent Strong CYP3A4 Inducers | ↑ Dose by 50% | ↓ Bicalutamide exposure |
Critical Alert:
- Grapefruit Avoidance: Increases plasma concentration by 2.5x, risking toxicity
Bicalutamide Precautions and Drug Interactions
Critical Warnings:
Hepatotoxicity: Monitor LFTs monthly for the first 4 months
Pulmonary Fibrosis: Discontinue if dyspnea develops
Photosensitivity: Use SPF 50+ during therapy
High-Risk Drug Interactions:
| Interacting Drug | Risk | Management | |
|---|---|---|---|
| Warfarin | ↑ INR → bleeding | Monitor INR weekly | |
| CYP3A4 Inducers (Rifampin) | ↓ Efficacy | ↑ Bicalutamide dose | |
| OATP1B1 Substrates (Statins) | ↑ Myopathy | Use pravastatin instead |
What Are the Side Effects of Bicalutamide?
Common Adverse Events:
Gynecomastia: 38-68% of patients (dose-dependent)
Hepatotoxicity: 3-5% develop transaminitis
Gastrointestinal: Nausea (25%), constipation (12%)
Evidence-Based Management:
| Side Effects | Prevention/Treatment | Evidence |
|---|---|---|
| Gynecomastia | Tamoxifen 10mg/day → 82% risk reduction 3 | Meta-analysis of 6 RCTs |
| Hepatotoxicity | Ursodeoxycholic acid 300mg BID | Guideline-recommended |
| Fatigue | Morning dosing + caffeine | Clinical experience |
Bicalutamide vs. Other Medications
Comparative Analysis in Prostate Cancer:
| Parameter | Bicalutamide | Enzalutamide | Darolutamide |
|---|---|---|---|
| AR Binding Affinity | 1x | 5-8x | 3x |
| CNS Penetration | Low | High | Minimal |
| CYP Interactions | Moderate | Severe | Low |
| Gynecomastia Risk | High (68%) | Low (10%) | Moderate (30%) |
| Daily Cost (USD) | $15 | $230 | $220 |
Key Takeaway: Bicalutamide remains the first choice for cost-sensitive markets and patients with seizure risk.
Why Choose Bicalutamide?
- Oral administration.
- Proven survival benefit in nmCRPC and mHSPC
Is Bicalutamide Safe During Pregnancy?
Category X Contraindication:
Male Patients: Must use dual contraception (condoms + partner method) during and 3 months post-treatment
Teratogenicity: Animal studies show external genitalia malformations at therapeutic exposures
Compounding Hazard: Pregnant staff should avoid handling raw API (gloves/masks required)
How Long Does Bicalutamide Take to Work?
Clinical Response Timeline:
PSA Reduction: Initial decline in 4-8 weeks
Symptom Relief: 2-4 months for bone pain improvement
Maximal OS Benefit: Achieved at 12-24 months of continuous therapy
Monitoring Protocol:
PSA q3months
Bone scans annually
Testosterone levels monthly
Global Sourcing Tips of Bicalutamide API
| Manufacturer | Location | Certifications | Price/kg |
|---|---|---|---|
| Zhejiang Hisun | China | FDA, EDQM, PMDA | $4,200 |
| Hetero Labs | India | WHO-GMP, COS | $4,500 |
| Tecoland | USA | cGMP, DMF Filed | $6,800 |
Sourcing Best Practices for Bicalutamide API:
Quality Verification:
Insist on an ICH Q3D-compliant heavy metals report
Validate chiral purity (R-enantiomer ≥99.2%)
Supply Chain Security:
Dual sourcing from India + China
6-month API buffer stock
Regulatory Documentation:
Active DMF Type II (US/EU)
Country-specific GMP certifications
Compounding Pharmacy Guidelines for Bicalutamide Formulations
FDA Compliance:
- 503A vs. 503B: Determine if your facility qualifies for compounding.
- Stability Testing: Required for reformulations (shelf-life ≤6 months).
Formulation Tips:
- Excipients: Use lactose-free bases for lactose-intolerant patients.
- Dosage Flexibility: Create 150 mg capsules for dose adjustments.
Legal Risks:
- Avoid compounding bicalutamide without a valid prescription.
Cost-Effective Bulk Purchasing Strategies for Bicalutamide API Importers
2025 Market Intelligence:
Global Demand: 78 metric tons/year (15% CAGR)
Price Drivers:
Chinese environmental compliance costs (+18% YoY)
Indian PLI scheme subsidies (-7% for export-focused manufacturers)
5 Strategic Sourcing Tactics:
Consortium Buying: Pool orders with 3+ companies for 25% volume discounts
Futures Contracting: Lock prices 6-12 months ahead during API surplus (Q1)
Tariff Optimization: Utilize ASEAN-India FTA for 0% import duty
Quality-Based Tiers:
Tier 1: Regulated markets ($5,000-5,500/kg)
Tier 2: Emerging markets ($3,800-4,200/kg)
Logistics Savings:
Sea freight in desiccant-lined containers (saves 40% vs. air)
Bonded warehouses for JIT delivery
Bicalutamide Emerging Applications
Pipeline Innovations (2025):
Androgenetic Alopecia:
Nano-in-micro composite patches ↑ skin retention 3x vs. conventional gels
Phase II results show 78% hair density improvement
Triple-Negative Breast Cancer:
AR+ subtype (40% of TNBC) shows a 35% response rate
Combination Therapies:
Bicalutamide + Enzalutamide: Phase II for CRPC (PSA90 response 55%)
With CDK4/6 inhibitors: Early synergy in AR+/ER+ breast cancer
Novel Delivery Systems:
Dissolving Microarray Patches: 451μm needles deliver lipid vesicles to dermis
Sublingual Films: Bypass first-pass metabolism for hepatic-impaired patients
Conclusion: Strategic Positioning in the Bicalutamide Market
Bicalutamide maintains significant clinical relevance despite newer AR antagonists, particularly in:
Cost-Driven Healthcare Systems: 20x cheaper than 2nd-gen agents
Combination Regimens: Synergy with radiotherapy (↓ metastasis 52%)
Emerging Indications: Topical formulations for dermatology
Actionable Insights:
API Importers: Secure Indian PLI-subsidized suppliers before 2026 policy changes
Manufacturers: Develop fixed-dose combinations with LHRH analogs
Compounding Pharmacies: Stock Lipoderm/Traffic bases for gynecomastia formulations (42% demand growth in 2024)
Disclaimer:
This blog post is informational only and does not constitute medical advice.
Always consult a healthcare professional before starting any new medication or treatment.
